Advertisement
Canada markets open in 22 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7324
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    84.29
    +0.72 (+0.86%)
     

  • Bitcoin CAD

    87,632.55
    +1,380.34 (+1.60%)
     

  • CMC Crypto 200

    1,386.53
    -10.00 (-0.72%)
     

  • GOLD FUTURES

    2,356.20
    +13.70 (+0.58%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.6800
    -0.0260 (-0.55%)
     

  • NASDAQ futures

    17,723.00
    +155.50 (+0.89%)
     

  • VOLATILITY

    15.57
    +0.20 (+1.30%)
     

  • FTSE

    8,114.54
    +35.68 (+0.44%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6831
    +0.0010 (+0.15%)
     
MARKETS LIVE BLOG:

STOCK FUTURES JUMP, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Lumos Pharma to Participate in December Investor Conferences

Lumos Pharma, Inc.
·2 min read

AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in December:

Piper Sandler Healthcare Conference

Date:

Monday, November 23, 2020

What:

Fireside chat with Lumos Pharma management

Management will host virtual one-on-one meetings during the conference on Wednesday, December 2, 2020. An on-demand download of the fireside chat is available as of November 23rd on the Piper Sandler conference portal and under “Events & Presentations” in the Investors & Media section of Lumos Pharma’s website.

Evercore ISI HealthCONx

Date:

Thursday, December 3, 2020

Time:

1:00-1:45PM ET

What:

Panel Discussion, “Easy Pills to Swallow: Oral Drugs for Large Endo Markets” – Chiasma, Crinetics, Lumos

Management will host virtual one-on-one meetings throughout the day on Thursday, December 3, 2020. A live webcast of the panel discussion will be available on the company’s website under “Events & Presentations” in the Investors & Media section of Lumos Pharma’s website.

Please contact your Piper Sandler and Evercore ISI sales representatives to register for these investor conferences and to schedule a virtual one-on-one meeting with the Lumos Pharma management team.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.